Clinical trials: Shingles
Herpes Zoster
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland.
- Trial name
- NCT07502560
- Testing
- Recombinant zoster vaccine
- Where
- 8 sites in Finland
- Volunteers
- 33,609 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Systemic Lupus Erythematosus
Zostavax in Systemic Lupus Erythematosus
Individuals with systemic lupus erythematosus (SLE, lupus) appear to be at increased risk for the development of shingles, a painful reactivation of the varicella zoster virus that causes chicken pox.
- Trial name
- NCT01474720
- Testing
- Zostavax vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Zoster, Zoster Varicella
Systems Biology of Zoster Vaccine
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
- Conditions
- Zoster, Zoster Varicella, Shingles, Chicken Pox
- Trial name
- NCT04047979
- Testing
- Shingrix®
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Emory University
Varicella
A Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
This study is a randomized and controlled Phase IV clinical trial.The purpose of this study is to evaluate the immunogenicity and safety of combined immunization with live attenuated varicella vaccine and inactivated hepatitis A…
- Trial name
- NCT05526820
- Testing
- The live attenuated varicella vaccine and the inactivated hepatitis A vaccine
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Postherpetic Neuralgia
Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia
Background: Acute herpes zoster causes severe neuropathic pain and may progress to postherpetic neuralgia (PHN). This study aims to evaluate ultrasound-guided thoracic paravertebral block with local anesthetic and steroid in…
- Trial name
- NCT07349680
- Testing
- Valacyclovir + Paracetamol (Acetaminophen) + Gabapentin (standard medical therapy), Ultrasound-guided thoracic paravertebral block (TPVB) with bupivacaine 0.25% + methylprednisolone 40 mg
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Measles, Mumps
Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
The primary study objectives are: To demonstrate that a 2-dose regimen of ProQuad® manufactured with recombinant Human Albumin (rHA) administered at a 3-month interval to healthy children of 11 months of age at the time of Dose 1…
- Conditions
- Measles, Mumps, Rubella, Varicella
- Trial name
- NCT00566527
- Testing
- ProQuad® manufactured with recombinant Human Albumin (rHA)
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients
The reactivation of varicella zoster virus (VZV) (herpes zoster (HZ)) is of substantial public health concern. Updated ACR recommendations for RA treatment suggest that RA patients aged ≥ 50 years should be vaccinated before…
- Trial name
- NCT03016884
- Testing
- Zostavax vaccine
- Where
- 3 sites in Israel
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Respiratory Syncytial Virus (RSV)
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults
This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
- Trial name
- PISSARRO (NCT06890416)
- Testing
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes Zoster, Shingles
ZOSTAVAX™ Safety and Immunogenicity in Korean Adults (V211-034)
This study will evaluate the safety, tolerability, and immunogenicity of ZOSTAVAX™ in Korean adults. Approximately 180 herpes zoster history negative subjects ≥ 50 years of age will be enrolled in the study.
- Trial name
- NCT01556451
- Testing
- Zoster Vaccine Live
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Zoster
Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine 1437173A in Healthy Ethnic Japanese Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in healthy ethnic Japanese adults.
- Trial name
- NCT01086449
- Testing
- Herpes Zoster Vaccine GSK 1437173A
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rheumatoid Arthritis, Varicella Zoster
Safety of Zostavax Vaccination in Rheumatoid Arthritis
Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age.
- Trial name
- NCT01506661
- Testing
- Zostavax (varicella zoster virus) vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Post Herpetic Neuralgia, Herpes Zoster
Treatment of Chronic Postherpetic Pain With Fat Grafting
This study evaluates the possible beneficial effect of fat grafting for post herpetic neuralgia.
- Trial name
- NCT03584061
- Testing
- Fat grafting
- Where
- Denmark
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Shingles
Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
Vaccination is the most effective way of preventing infectious diseases. Despite the success of vaccines in general, vaccines induce diminished antibody responses and lower protection in the elderly in particular.
- Trial name
- NCT01331161
- Testing
- ZOSTAVAX
- Where
- 2 sites in United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Emory University
Herpes Zoster, Varicella-zoster Vaccine
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose.
- Trial name
- NCT01245751
- Testing
- Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Simplex, Herpes Zoster
Activation of Alternative Cellular Energy (ACE) Pathway in the Therapy of Herpes Virus Infections
The research question to be addressed is whether indirect phototherapy based activation of the body's alternative cellular energy (ACE) pathway will lead to expedited healing of active herpes simplex virus (HSV) and herpes zoster…
- Trial name
- NCT00642785
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institute of Progressive Medicine
Immune System Responses and Trained Immunity After AS01 Administration, Healthy Adult
Improving Vaccine Protection for Adults
As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines.
- Trial name
- NCT07527247
- Testing
- AS01 adjuvant (0.5 mL intramuscular), YF17D (Stamaril, Sanofi-Pasteur)
- Where
- Singapore
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Shingles
Safety, Tolerability, and the Body's Ability to Develop Resistance to an Investigational Vaccine for Shingles (V211-007)
The purpose of this study is to determine the immunity (the body's protection) against shingles after receiving two doses of an investigational vaccine or placebo (a look alike vaccine with no active ingredients).
- Trial name
- NCT00109122
- Testing
- zoster vaccine live (Oka/Merck)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Herpes Zoster
Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine
This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.
- Trial name
- NCT05718037
- Testing
- Recombinant Zoster Vaccine, Zoster Vaccine Recombinant, Adjuvanted
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.